Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05390073
  4. Details
NCT05390073 Clinical Trial

Growth Hormone in EB

Epidermolysis Bullosa Dystrophica Clinical Trial

Official title:
Assessment of Growth Hormone and Insulin-like Growth Factor 1 in Children With Epidermolysis Bullosa Dystrophia

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05390073
Other study ID # Growth in EB
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 25, 2022
Est. completion date June 15, 2022

Study information
Verified date May 2022
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Growth is extremely affected in epidermolysis bullosa patients

Description:

Studying the role of growth hormone and ILGF-1 in EB may pave the to new therapeutic modality that could improve the growth in those children and avoid the irreversible sequelae that affected subjects experience after adulthood

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 50
Est. completion date June 15, 2022
Est. primary completion date June 10, 2022
Accepts healthy volunteers
Gender All
Age group 1 Month to 12 Years
Eligibility Inclusion Criteria: - Children with EB dystrophica Exclusion Criteria: - Adults with the same disease

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• growth hormone level and insulin like growth factor 1
laboratory test

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Cairo University

Outcome
Type Measure Description Time frame Safety issue
Primary level of growth hormone and insulin like growth factor 1 laboratory test 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT01263379 - Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa Phase 1/Phase 2
Completed NCT01716169 - Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care N/A
Completed NCT00951964 - Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) Phase 2
Recruiting NCT03269474 - Computational Drug Repurposing for All EBS Cases
Recruiting NCT01019148 - Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Completed NCT03241628 - Proof of Concept Study for a Dressing Glove N/A
Recruiting NCT04213703 - A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Not yet recruiting NCT06177353 - Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro
Recruiting NCT06007235 - CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa N/A
Active, not recruiting NCT05843994 - Artificial Intelligence Patient App for RDEB SCCs
Active, not recruiting NCT05033574 - The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
Completed NCT04908215 - INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa Phase 2
Terminated NCT00587223 - Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB) Phase 3
Active, not recruiting NCT04171661 - Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa Early Phase 1
Terminated NCT00533572 - Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer N/A
Completed NCT00904163 - Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa N/A
Recruiting NCT03786237 - Rigosertib for RDEB-SCC Phase 1/Phase 2